New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:13 EDTZIOPZiopharm trial reaches target number of progression-free survival events
ZIOPHARM Oncology announced that the Phase 3, PICASSO 3, trial of palifosfamide in first-line metastatic soft tissue sarcoma has reached its target number of progression-free survival events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial whose primary endpoint is PFS. According to the protocol and statistical plan, reaching the target number of PFS events leads to completion of the blinded data collection process and then formal efficacy analysis by the Independent Data Monitoring Committee. The company will announce topline results from this trial during the last week of March, it said. The company said, "Reaching the target number of progression events for PICASSO 3 positions us one step closer to understanding palifosfamide's full potential for this significant unmet medical need. With a positive study outcome, palifosfamide has the potential to become the first new treatment option in nearly 30 years for patients with first-line metastatic soft tissue sarcoma."
News For ZIOP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
19:31 EDTZIOPOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 1%. ALSO HIGHER: Repros Therapeutics (RPRX), up 21.9% after announcing acceptance for filing of NDA its enclomiphene citrate product... TCP International (TCPI), up 13.7% after announcing that product validation is proceeding as expected... Intrexon (XON), up 2.4% after signing a CRADA with NCI for RTS platform. DOWN AFTER EARNINGS: Sigma Designs (SIGM), down 2.8%... Micron Technology (MU), down 1.7%. ALSO LOWER: Conatus Pharmaceuticals (CNAT), down 4.4% after filing to sell common stock... TrueCar (TRUE), down 1.8% after being initiated with a Sell at B. Riley... ZIOPHARM Oncology (ZIOP), down 1.8% after filing to sell 11.72M shares of common stock for holders.
18:50 EDTZIOPZiopharm files to sell 11.72M shares of common stock for holders
March 30, 2015
10:10 EDTZIOPMizuho says scale, speed of Intrexon-Ziopharm deal a positive
Subscribe for More Information
09:27 EDTZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTZIOPZiopharm-Intrexon announce collaboration with Merck KGaA for CAR-T products
ZIOPHARM Oncology (ZIOP) and Intrexon (XON) announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell, or CAR-T, products with Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAY). Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM's other oncology programs will continue through its Exclusive Channel Collaboration with Intrexon.
March 27, 2015
12:28 EDTZIOPIntrexon, Ziopharm mentioned as stock picks by Bill Miller on CNBC
March 25, 2015
11:01 EDTZIOPZiopharm May volatility elevated at 129
Ziopharm April call option implied volatility is at 123, May is at 129, July is at 106; compared to its 26-week average of 120 according to Track Data, suggesting large April price movement.
March 23, 2015
06:04 EDTZIOPStocks with implied volatility above IV index mean; ZIOP BBRY
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use